- Ab04123-23.0 Anti-PD-L1 [D7A8]
- Rabbit IgG
- Ships in 5-6 weeks
- Ab04123-30.11 Anti-PD-L1 [D7A8]
- scFv fragment (His)
- Ships in 5-6 weeks
Recombinant monoclonal antibody to PD-L1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody D7A8.
UniProt Accession Number of Target Protein: Q9NZQ7
Alternative Name(s) of Target: CD274; B7-H1; hPD-L1; PDCD1 ligand 1; Programmed cell death 1 ligand 1; B7 homolog 1
Immunogen: The original antibody was isolated by panning a phage display library against PD-L1.
Specificity: The antibody is specific for PD-L1.
Application Notes: The scFv format of the antibody,together with B1C4A7, was used for constructing in the bispecific antibody (A7-A8)-LALA. The scFv format and the bispecific antibody could strongly bind to the recombinant human and mouse PDL1 (EC50 = 0.121 nM and 0.172 nM, respectively for scFv and 0.088 nM and 0.160 nM, respectively for the bispecific antibody). The scFv format and the bispecific antibody could strongly block ligand PDL1 binding to its receptor PD1. IC50 for hPDL1-hPD1 interaction was 2.51 nM for the bispecific antibody, and 3.04 nM for dsD7A8-LALA. IC50 for the mPDL1-mPD1 interaction was 5.59 nM for the bispecific antibody, versus 2.80 nM for dsD7A8-LALA. The bispecific antibody could bind to cell expressed human PDL1 and mouse PDL1. The EC50 values of the bispecific antibody to MDA-MB-231 and B16-F10 were 0.223 nM and 0.122 nM, respectively; for dsD7A8 to MDA-MB-231 and B16-F10 the values were 0.159 nM and 0.042 nM, respectively. The bispecific antibody associated to PDL1 fast and dissociated slowly (KD = 1.2 pM for the bispecific and 7.7 pM for dsD7A8-LALA). Further, the bispecific antibody could bind to VEGFR2 and PDL1 simultaneously, as determined by by cross binding ELISA. The bi-specific antibody was able to stimulate cytokine IL2 and INFy secretion. The effect of the original and bispecific antibodies was examined on CT26 murine colon carcinoma cells. The results indicate that B1C4A7, D7A8, and BsAb (A7-A8) reduced volumes of the tumor. Further, the combination of the two antibodies (B1C4A7 and D7A8) and BsAb (A7-A8) were more potent than two individual antibodies alone in reducing tumor volume. The effect of the original and bispecific antibodies was examined on MC38 murine colon carcinoma cells. D7A8 and BsAb (A7-A8), and combination of B1C4A7 and D7A8 completely inhibited the tumor growth (EP3411068A4).
Antibody first published in: PMID: